Essential thrombocythemia (ET)

Antonio Cuneo, Francesco Cavazzini

Hematology Section, Department of Biomedical Sciences, University of Ferrara, Corso Giovecca 203, Ferrara, Italy

Published in Atlas Database: August 2006

Online updated version: http://AtlasGeneticsOncology.org/Anomalies/ET.html
DOI: 10.4267/2042/38380


This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence.
© 2007 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Clinical and pathology

Disease
Chronic myeloproliferative syndrome

Phenotype / cell stem origin
The disease is a chronic myeloproliferative disorder originating from a mutated pluripotent stem cell capable of producing red blood cells, granulocytes and megakaryocytes. In some cases, B-lymphocyte involvement by the clonal proliferation was documented. T-lymphocytes are not involved by the malignant process and nonclonally derived granulocytes may coexist with clonal cells in patients with ET.

Epidemiology
ET has an annual incidence of 1.5 to 2.4 patients /100,000. The disease incidence may show a peak around 30 years in females, with a second peak in the elderly with a 1:1 male-to-female ratio. The average age at diagnosis is 50-60 years.

Clinics
The disease is diagnosed in the presence of a sustained increase of the platelet count (>600 X 10^9/L) over at least 1 month without an obvious explanation.
In the majority of patients the disease remains asymptomatic for many years. The disease symptoms are usually related to arterial thrombosis and, less frequently, deep venous thrombosis, which are more frequent in the untreated patient. Death may occur following major ischemic events or leukemic transformation.

Cytology
The peripheral blood smear shows thrombocytosis without obvious morphologic abnormalities of the white blood cells and erythrocytes. Megathrombocytes may be seen. The bone marrow is hypercellular with enlarged megakaryocytes, which may tend to aggregate in small clusters. At diagnosis a moderate increase of reticulin fibers may be observed, whereas the presence of marked fibrosis is a diagnostic exclusion criteria.

Treatment
Treatment should be considered for patients at risk of thrombosis (age > 60 years, previous ischemic events, platelet > 1500 X 10^9/L). Low-dose aspirin or other anti-platelet agents are used. Hydroxyurea is effective in reducing the platelet count and the incidence of thrombotic events. Interferon or anagrelide may be used in young patients.

Evolution
Leukemic transformation may occur in 3-10% of the cases. Transformation into a stage indistinguishable form idiopathic myelofibrosis was documented in 5% of the cases.

Prognosis
The large majority of the patients survive > 10 years. No significant difference between life expectancy of ET patients and age-matched subjects was observed in a study.

Cytogenetics

Cytogenetics morphological
Less than 10% of the patients show a clonal chromosome defect at diagnosis. Recurrent abnormalities include total/partial trisomy 1q, trisomy 8 and trisomy 9, del(13q) and del(20q). Rearrangements of chromosome 17, leading to 17p deletion can be frequently associated with Leukemic transformation.
**Cytogenetics molecular**

a) Fluorescence in situ hybridization (FISH) and molecular studies:
FISH may be more sensitive than conventional karyotyping for the detection of chromosome deletions.

b) Janus Kinase JAK2 mutation:
A valine to phenylalanine substitution at position 617 (JAK2 V617F mutation) is present in 50-75% of the patients leading to constitutive kinase activity. Unlike polycythemia vera, mutated homozygous cells are not found in ET. In 1% of the patients a gain-of-function mutation of the thrombopoietin receptor (MPL) gene can be found, determining activation of the JAK-STAT pathway.

**References**


Campbell PJ, Green AR. Management of Polycythemia Vera and Essential Thrombocytopenia. ASH Educational Book 2005;201-208.


This article should be referenced as such: